Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

(2018) Michael R. Savona et al.   CLINICAL CANCER RESEARCH

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

(2018) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells

(2016) Nobuaki Fukushima et al.   CANCER SCIENCE

TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

(2016) Maël Heiblig et al.   Mediterranean Journal of Hematology and Infectious Diseases

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects

(2015) J. Wellbrock et al.   CLINICAL CANCER RESEARCH

Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity

(2015) F. H. Heidel et al.   CLINICAL CANCER RESEARCH

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

(2015) Raoul Tibes et al.   Journal of Hematology & Oncology

GLI2 inhibition abrogates human leukemia stem cell dormancy

(2015) Anil Sadarangani et al.   Journal of Translational Medicine

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

(2015) Michael R Migden et al.   LANCET ONCOLOGY

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

(2015) A K Burnett et al.   LEUKEMIA

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

(2015) Giovanni Martinelli et al.   Lancet Haematology

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults

(2014) Heidi D. Klepin et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting hedgehog in hematologic malignancy

(2012) D. A. Irvine et al.   BLOOD

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

(2012) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

(2012) M. A. Sekeres et al.   HAEMATOLOGICA

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms

(2011) Chi Young Ok et al.   AMERICAN JOURNAL OF PATHOLOGY

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

(2011) A K Burnett et al.   LEUKEMIA

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells

(2010) K C S Queiroz et al.   ONCOGENE

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD